Oncotelic has two pharmacological agents in clinical trials to manage Covid-19, the disease caused by the SARS-CoV-2 virus. OT-101 and ARTIVeda both work by inhibiting TGF-β to neutralize the SARS-CoV-2 virus.

Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications, the company tested OT-101 and Artemisinin, both of which showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the their mechanism of action.

Oncotelic COVID-19 Solution


TGF-β inhibitor to address the COVID-19 pandemic in India. A similar product, ArtiShield, will be available outside of India.

Learn more about ARTIVeda >


OT-101 has a similar mechanism of action as ARTIVeda, and is currently in phase 2 testing.

Copyright © 2020 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.